海辰药业：2025年半年度归属于上市公司股东的净利润同比增长17.87%

Core Viewpoint - Haichen Pharmaceutical reported a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential in the pharmaceutical industry [2] Financial Performance - The company achieved a revenue of 308,572,571.42 yuan for the first half of 2025, representing a year-on-year growth of 30.46% [2] - The net profit attributable to shareholders of the listed company was 29,157,742.41 yuan, reflecting a year-on-year increase of 17.87% [2]